Literature DB >> 20562123

Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice.

B Lubamba1, J Lebacq, G Reychler, E Marbaix, P Wallemacq, P Lebecque, T Leal.   

Abstract

Sildenafil and vardenafil, two selective inhibitors of phosphodiesterase type 5 (PDE5) are able, when applied by intraperitoneal injection, to activate chloride transport in cystic fibrosis (CF) mice homozygous for the F508del mutation. Oral treatment with the drugs may be associated with adverse haemodynamic effects. We hypothesised that inhaled PDE5 inhibitors are able to restore ion transport in F508del CF airway epithelium. We developed a restraint-free mouse chamber for inhalation studies. PDE5 inhibitors were nebulised for 15 min at concentrations adjusted from recommended therapeutic oral doses for male erectile dysfunction. We measured in vivo nasal transepithelial potential difference 1 h after a single inhalation of sildenafil, vardenafil or tadalafil in F508del CF and normal homozygous mice. After nebulisation with the drugs in F508del mice, chloride transport, evaluated by perfusing the nasal mucosa with chloride-free buffer containing amiloride followed by forskolin, was normalised; the forskolin response was increased, with the largest values being observed with tadalafil and intermediate values with vardenafil. No detectable effect was observed on sodium conductance. Our results confirm the role of PDE5 inhibitors in restoring chloride transport function of F508del CF transmembrane conductance regulator protein and highlight the potential of inhaled sildenafil, vardenafil and tadalafil as a therapy for CF.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20562123     DOI: 10.1183/09031936.00013510

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  17 in total

Review 1.  Advances in device and formulation technologies for pulmonary drug delivery.

Authors:  John Gar Yan Chan; Jennifer Wong; Qi Tony Zhou; Sharon Shui Yee Leung; Hak-Kim Chan
Journal:  AAPS PharmSciTech       Date:  2014-04-12       Impact factor: 3.246

Review 2.  Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.

Authors:  George M Solomon; Susan G Marshall; Bonnie W Ramsey; Steven M Rowe
Journal:  Pediatr Pulmonol       Date:  2015-06-19

3.  Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease.

Authors:  J L Taylor-Cousar; C Wiley; L A Felton; C St Clair; M Jones; D Curran-Everett; K Poch; D P Nichols; G M Solomon; M T Saavedra; F J Accurso; J A Nick
Journal:  J Cyst Fibros       Date:  2014-11-13       Impact factor: 5.482

Review 4.  Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis.

Authors:  Peter A Sloane; Steven M Rowe
Journal:  Curr Opin Pulm Med       Date:  2010-11       Impact factor: 3.155

5.  Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice.

Authors:  Mathilde Beka; Teresinha Leal
Journal:  J Vis Exp       Date:  2018-07-04       Impact factor: 1.355

Review 6.  New and emerging targeted therapies for cystic fibrosis.

Authors:  Bradley S Quon; Steven M Rowe
Journal:  BMJ       Date:  2016-03-30

7.  Sildenafil improves vascular endothelial function in patients with cystic fibrosis.

Authors:  Paula Rodriguez-Miguelez; Nichole Lee; Matthew A Tucker; Gábor Csányi; Kathleen T McKie; Caralee Forseen; Ryan A Harris
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-08-31       Impact factor: 4.733

8.  PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis.

Authors:  Sabrina Noel; Barbara Dhooghe; Teresinha Leal
Journal:  Front Pharmacol       Date:  2012-09-18       Impact factor: 5.810

Review 9.  Nitric Oxide System and Bronchial Epithelium: More Than a Barrier.

Authors:  María Amparo Bayarri; Javier Milara; Cristina Estornut; Julio Cortijo
Journal:  Front Physiol       Date:  2021-06-30       Impact factor: 4.566

10.  Dysregulated proinflammatory and fibrogenic phenotype of fibroblasts in cystic fibrosis.

Authors:  François Huaux; Sabrina Noel; Barbara Dhooghe; Nadtha Panin; Sandra Lo Re; Dominique Lison; Pierre Wallemacq; Etienne Marbaix; Bob J Scholte; Patrick Lebecque; Teresinha Leal
Journal:  PLoS One       Date:  2013-05-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.